We are live on ! Find out more

47 hedge funds and large institutions have $46.4M invested in Exagen in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 25 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

9.92% more ownership

Funds ownership: 56.01%65.93% (+9.9%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

11% less funds holding

Funds holding: 5347 (-6)

36% less capital invested

Capital invested by funds: $73M → $46.4M (-$26.6M)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

60% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 25

Holders
47
Holders Change
-6
Holders Change %
-11.32%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
10
Reduced
25
Closed
13
Calls
$1.54M
Puts
Net Calls
+$1.54M
Net Calls Change
-$313K

XGN Hedge Fund Activity: Q2 2022 in Review

47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q2 2022, worth a combined $46.4M — down 36% from $73M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of XGN and 8 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 10 added.

The largest buyer was HighTower Trust, opening a new position worth an estimated $15.6M. The largest seller was BlackRock, cutting an estimated $2.9M.

  • 47 institutional investors held Exagen (XGN) as of Q2 2022, down from 53 in Q1 2022.
  • Funds reported $46.4M of Exagen stock for Q2 2022, down 36% quarter-over-quarter.
  • 8 funds opened new Exagen positions in Q2 2022 and 13 closed out, a net change of -5 holders.
  • The largest Exagen buyer in Q2 2022 was HighTower Trust, an estimated $15.6M added.
  • The largest Exagen seller in Q2 2022 was BlackRock, an estimated $2.9M sold.

Based on aggregated 13F filings for Q2 2022.